A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia
Not yet recruitingOBSERVATIONAL
Enrollment
22
Participants
Timeline
Start Date
September 1, 2025
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2027
Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG
Parsaclisib
parsaclisib 40mg qd
All Listed Sponsors
lead
Peking Union Medical College Hospital
OTHER
NCT07149818 - A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic Anemia | Biotech Hunter | Biotech Hunter